1. Scrip
  2. >>Archive

Mylan inks deal with Biocon for insulin analogs but preps for more in India?

 
• By Anju Ghangurde

Mylan, the world's third largest generics and specialty pharmaceutical company, is upping its engagement with Indian firms. It has entered into a collaboration with Biocon, India's largest biotechnology company by revenue, to develop and commercialize generic versions of three insulin analog products, amid talk that it may also be keen to snap up a formulations plant.

Mylan, the world's third largest generics and specialty pharmaceutical company, is upping its engagement with Indian firms. It has entered into a collaboration with Biocon, India's largest biotechnology company by revenue, to develop and commercialize generic versions of three insulin analog products, amid talk that it may also be keen to snap up a formulations plant.

The latest alliance builds on a 2009 pact between Mylan and Biocon for certain high-value generic biologic compounds – such as trastuzumab, peg-filgrastim and eternacept, among others - for the...

More from Archive

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.